Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311

Invivyd Inc. (NASDAQ:IVVD) is one of the best growth stocks under $30 to buy now. On June 9, Invivyd dosed the first participants in its LIBERTY Phase 3 clinical trial, a study comparing the safety and tolerability of its monoclonal antibody candidate, VYD2311, against mRNA COVID-19 vaccines. The randomized, double-blind trial involves ~210 healthy adults and includes 3 treatment arms to assess the effects of VYD2311 alone, the vaccine alone, and both administered concurrently. Invivyd expects to report topline data in Q3 2026, which will support its ongoing regulatory efforts.

This trial is a key component of Invivyd’s broader REVOLUTION clinical program, which seeks to position VYD2311 as a more tolerable, vaccine-alternative prophylactic for COVID-19. Chairman Marc Elia highlighted the urgent need for prevention options that avoid the systemic side effects associated with mRNA vaccines, noting that concerns over these reactions have contributed to declining booster uptake. The study aims to provide clinical evidence that could differentiate the safety profile of mAb-mediated prophylaxis from traditional immunization.

Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311

15 States with the Best Healthcare in the US

VYD2311 is an investigational antibody engineered for neutralization of contemporary COVID-19 lineages, using an intramuscular administration route designed for patient convenience. LIBERTY results will complement data from the company’s pivotal DECLARATION Phase 3 trial, which is currently evaluating the efficacy of VYD2311 in a broader population of ~2,400 participants. Together, these trials form the foundation for Invivyd Inc.’s (NASDAQ:IVVD) goal of establishing a new standard of care in COVID-19 prevention.

Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, utilizing a proprietary platform to deliver durable therapies.

While we acknowledge the risk and potential of IVVD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IVVD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1